Carlos Becerra, MD
Although response rates were low, patients with metastatic pancreatic cancer experienced a significant decrease in tumor burden after being treated with chimeric antigen receptor (CAR) T cells, according to Carlos Becerra, MD.
on Gastrointestinnal Cancers, Becerra, the interim chief of Oncology for Baylor Scott & White Health – North Texas, and medical director of the Swim Across America Innovative Clinical Trials Center at the Charles A. Sammons Cancer Center at Baylor University Medical Center at Dallas, discussed the current management and emerging therapies for patients with pancreatic cancer.
OncLive: Can you provide an overview of your presentation on the management of pancreas cancer?
: Pancreas cancer is one of the leading causes of death related to cancer. We do not have good treatments. We have made some progress in pancreas cancer, particularly with metastatic disease, since many patients present to an oncologist already with metastatic disease.
... to read the full story